Overview

Mucinex® for Treatment of Filamentary Keratitis

Status:
Completed
Trial end date:
2018-07-01
Target enrollment:
0
Participant gender:
All
Summary
It is a pilot study aimed to determine if oral Mucinex® is effective in reducing the amount of corneal filaments and improving symptomology in subjects with filamentary keratitis.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Massachusetts Eye and Ear Infirmary
Treatments:
Chlorpheniramine, phenylpropanolamine drug combination
Guaifenesin
Phenylpropanolamine
Criteria
Inclusion Criteria:

- Patients with filamentary keratitis

- 18 years and older

Exclusion Criteria:

- Active ocular surface infection of any type

- Recent ocular surgery (<30 days) history of nephrolithiasis as Mucinex® has been
associated in rare cases of development of kidney stones

- Schirmer's test<3mm

- History of hypersensitivity to Mucinex®

- Concurrent eye disease requiring immediate initiation of a new treatment (e.g. topical
steroids) restriction for water intake can exacerbate the risk of nephrolithiasis.